Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction
Brief Summary: The primary objective of this study is to establish the effects of a single bolus of EPO, administered within three hours after a primary PCI for a first acute myocardial infarction, on left ventricular function.


Options:
A: Inclusion Criteria:

* Patients with ST-Segment elevation myocardial infarction \<24 h from pain onset
* Successful primary PCI and left ventricular ejection fraction \<50%
* Informed, written consent
* In women with childbearing potential a pregnancy test is mandatory

Exclusion Criteria:

* Age \< 18 and \> 80 years
* Cardiogenic shock
* pericarditis
* thrombolysis for the index infarction
* malignancies/other comorbid conditions with life expectancy \< 1 year
* previous myocardial infarction
* planned staged PCI or prior PCI within 30 days from index procedure
* uncontrolled hypertension \>160/100mmHg unresponsive to therapy
* epilepsy
* active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary bleeding, recent trauma or major surgery \< 1 month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection; patient's refusal to blood transfusion
* hematologic disorders such as essential thrombocytosis, megakaryoblastic leukemia, polycythemia vera
* relevant hematologic deviations: hemoglobin \< 100 g/l or hemoglobin \> 160 g/l platelet count \< 100 x 10\^9 cells/l or platelet count \> 600 x 10\^9 cells/l
* any contraindication to magnetic resonance imaging: electronically, magnetically and mechanically activated implants such as cardiac pacemakers, automatic cardioverter defibrillators, joint prostheses, surgical/vascular clips/ hearing aids, neurostimulators, infusion pumps etc metallic splinters in the eye ferromagnetic haemostatic clips in the central nervous system cochlear implants lead wires or similar wires prosthetic heart valves, if dehiscence is suspected non-ferromagnetic stapedial implants, hemostatic clips
* glomerular filtration rate \< 30 ml/min or serum creatinine \> 30 mg/l or dependence on renal dialysis
* chronic liver disease with GOT \> 5-fold over the normal range
* allergy to erythropoietin/true anaphylaxis after prior exposure to contrast media
* phenylketonuria
* previous enrollment in this trial
* women who are known to be pregnant, who are of childbearing potential and test positive for pregnancy, who have given birth within the last 90 days, who are breastfeeding
* patient's inability to fully cooperate with the study protocol
* other contraindication according to the summary of product characteristics of recombinant human erythropoietin beta (NeoRecormon®)
B: Inclusion Criteria:

* ACS with persistent ST elevation
* First episode
* Symptoms onset \< 12 hours
* Eligible for angioplasty
* Culprit coronary artery occluded (TIMI flow 0-1) at admission, and then adequately reperfused (TIMI flow 2-3) prior to EPO injection

Exclusion Criteria:

* Cardiogenic shock
* Cardiac arrest
* Currently receiving EPO
* Pregnancy
C: Inclusion Criteria:

Successful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by:

* chest pain suggestive for acute myocardial infarction
* symptom onset \< 12 hour before hospital admission, or \< 24 hour in case ongoing ischemia
* ECG with ST-T segment elevation \> 1 mV in 2 or more leads
* TIMI flow 0/1 before primary PCI on diagnostic coronary angiography;

Exclusion Criteria:

* Hemoglobin levels \> 10.6 mmol/L;
* Anticipated additional revascularisation within 4 months;
* Cardiogenic shock;
* Presence of other serious medical conditions
* Pregnancy/breast feeding
* Malignant hypertension
* End stage renal failure (creatinin \> 220 micromol/l)
* Previous treatment with rh-EPO
* Blood transfusion \<12 weeks prior to randomisation
* Polycythemia vera
* Previous acute myocardial infarction
* Concomitant inflammatory or malignant disease
* Recent trauma or major surgery
* Unwilling to sign informed consent
* Atrial fibrillation
D: Inclusion Criteria:

* Patients at risks for acute tubular necrosis (patients with mechanical ventilation, patients with sepsis, in the post-operative state, with hemodynamic impairment or with previous chronic renal failure.
* Consent form signed

Exclusion Criteria:

* Patients with malignant hypertension
* Patients with systolic BP \> 150 mmHg at enrollment
* Patients with Hb level \> 120g/L
* Patients with acute coronaropathy
* Pregnancy
* Patients with urine output \< 600 ml/12 h

Answer: C